Literature DB >> 25432480

Pharmacologic and surgical interventions to improve functional capacity in heart failure.

Antonio Abbate1, Benjamin W Van Tassell2, Justin M Canada3, Dave L Dixon2, Ross A Arena4, Giuseppe Biondi-Zoccai5.   

Abstract

Heart failure (HF) is a clinical syndrome of breathlessness, lower extremity swelling, fatigue, and exercise intolerance affecting a large portion of the population worldwide, and associated with premature death. Despite improvement in the management of HF, many patients remain unable to complete activities of daily living without experiencing exertional symptoms. Although prevention of death in patients with HF is imperative, treatment of symptoms and improving functional capacity are equally important goals. This article discusses treatments (medical and surgical) associated with improved functional capacity in HF.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Device; Drugs; Functional capacity; Heart failure; Surgery; Treatments

Mesh:

Substances:

Year:  2014        PMID: 25432480     DOI: 10.1016/j.hfc.2014.08.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  3 in total

1.  Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

Authors:  Salvatore Carbone; Justin M Canada; Hayley E Billingsley; Dinesh Kadariya; Dave L Dixon; Cory R Trankle; Leo F Buckley; Roshanak Markley; Chau Vo; Horacio Medina de Chazal; Sanah Christopher; Raffaella Buzzetti; Benjamin W Van Tassell; Antonio Abbate
Journal:  Diabetes Obes Metab       Date:  2018-04-23       Impact factor: 6.577

Review 2.  Lifestyle Interventions with a Focus on Nutritional Strategies to Increase Cardiorespiratory Fitness in Chronic Obstructive Pulmonary Disease, Heart Failure, Obesity, Sarcopenia, and Frailty.

Authors:  Hayley Billingsley; Paula Rodriguez-Miguelez; Marco Giuseppe Del Buono; Antonio Abbate; Carl J Lavie; Salvatore Carbone
Journal:  Nutrients       Date:  2019-11-21       Impact factor: 5.717

3.  The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.

Authors:  Salvatore Carbone; Hayley E Billingsley; Justin M Canada; Edoardo Bressi; Brando Rotelli; Dinesh Kadariya; Dave L Dixon; Roshanak Markley; Cory R Trankle; Richard Cooke; Krishnasree Rao; Keyur B Shah; Horacio Medina de Chazal; Juan Guido Chiabrando; Alessandra Vecchié; Megan Dell; Virginia L Mihalick; Roberta Bogaev; Linda Hart; Benjamin W Van Tassell; Ross Arena; Francesco S Celi; Antonio Abbate
Journal:  Diabetes Metab Res Rev       Date:  2020-06-15       Impact factor: 4.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.